Antibody Information

General Information of This Antibody

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

MRG-001 [Phase 1]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Objective Response Rate (ORR)	23.81% (among 21 pts who had at least one tumor assessment) 33.33% (in the 1.8 mg/kg cohort, DLBCL) 66.7% ( in the 2.5 mg/kg cohort, FL)
Patients Enrolled	CD20-positive relapsed or refractory (R/R) B-cell non Hodgkin lymphoma (NHL).
Administration Dosage	Six dose levels ranging from 0.15 to 2.50 mg/kg, intravenously once every 3 weeks (Q3W) for a maximum of 6 treatment cycles.
*Related Clinical Trial*
NCT Number	NCT05155839	Clinical Status	Phase 1
Clinical Description	An open-label, multicenter, first-in-human, phase 1 dose-escalation and expansion clinical study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of MRG001 in patients with CD20-positive relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
Primary Endpoint	Rp2D=1.80 mg/kg.
Other Endpoint	Among 21 pts who had at least one tumor assessment, ORR=23.81% , PR rate=19.05% (N=4),CR rate=4.76% (N=1).
Experiment 2 Reporting the Activity Date of This ADC				[2]
*Related Clinical Trial*
NCT Number	NCT05844527	Clinical Status	Phase 2
Clinical Description	Safety and efficacy of MRG-001 in wound healing in pre-abdominoplasty surgical excisions and scar appearance in subjects undergoing abdominoplasty.

References

Ref 1	A Dose Escalation Phase Ia Study of Anti-CD20 Antibody Drug Conjugate, MRG001 in Relapsed/Refractory Advanced Non-Hodgkin Lymphom. Blood. (2021) 138 (Supplement 1): 2490.
Ref 2	Safety and Efficacy of MRG-001 in Wound Healing and Scar Appearance in Pre-Abdominoplasty Surgical Excisions, NCT05844527